Market cap
$4.6m
End-of-day close multiplied by current shares on issue.
MEE · NZX
Me Today is an NZX-listed consumer / wellness products company with HY22 - HY26 of published result briefings.
Snapshot
HY26, released 26 February 2026
| Metric | Value | Change |
|---|---|---|
| Revenue | $2.6m | ↓ -31.7% |
| EBITDA | -$0.83m | ↑ +53.8% |
| NPAT | $3.2m | ↑ +233.3% |
| Operating cash flow | -$1m | ↑ +4.6% |
| OCF / EBITDA % | 120.8% | ↑ +62.3pp |
| Net debt | $0.02m | ↓ -99.8% |
| Net debt / EBITDA | -0.03x | ↑ +99.6% |
| ROE % | 104.7% | ↑ +295.9pp |
| PBT | -$0.9m | ↑ +62.5% |
| FCF pre-lease | -$1.1m | ↓ -1.8% |
Source: latest published briefing (HY26, released 26 February 2026). Change compares against the prior equivalent period: HY25, released 28 February 2025.
Valuation
A compact read on what the market price implies next to the latest filing data. The numbers are a starting point for comparison, not a recommendation.
The latest close and share count context for the market price.
Market cap
$4.6m
End-of-day close multiplied by current shares on issue.
How the market price compares with recent earnings and cash-flow inputs.
P/E
Not available
Not meaningful when recent earnings are negative.
EPS
-0.00
Recent filing-derived earnings per share.
PEG
Not available
Not available for this company right now.
EV/EBITDA
Not available
Not meaningful when recent EBITDA is negative.
P/FCF
Not available
Not meaningful when free cash flow is negative or unavailable.
P/B
1.52x
Market value compared with latest reported equity.
Yield and fund-style valuation where the company shape supports it.
Dividend yield
0.0%
Trailing dividends compared with the latest close.
Total return
Not available
Available once dividend and adjustment data are verified.
Chat
Ask follow-up questions about Me Today's latest result and company history.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Informational only. No buy, sell, hold, price-target, or personal financial advice.
Longitudinal view
The latest period is shown first.
| Metric | HY266 MONTHS26 February 2026 | FY2512 MONTHS28 August 2025 | HY256 MONTHS28 February 2025 | FY2412 MONTHS29 August 2024 | HY246 MONTHS28 February 2024 | FY2312 MONTHS29 August 2023 | HY236 MONTHS1 March 2023 | FY2112 MONTHS29 August 2022 | HY226 MONTHS29 November 2021 | Trend |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.6m | $7.5m | $3.7m | $5m | $2.3m | $7.9m | $3.6m | $8.3m | $2.4m | Chart |
| Revenue growth % | -31.7% | 48.1%Outside range high revenue growth. 48.1%; 3-period range -36.2% to 14.7%. Revenue growth: 48.1%, above normal range; 3-period mean -8.8%, range -36.2%-14.7%. | 64.2% | -36.2%Outside range low revenue growth. -36.2%; 3-period range -4.7% to 48.1%. Revenue growth: -36.2%, below normal range; 3-period mean 19.3%, range -4.7%-48.1%. | -36.8%Outside range low revenue growth. -36.8%; 4-period range -31.7% to 469.6%. Revenue growth: -36.8%, below normal range; 4-period mean 137.8%, range -31.7%-469.6%. | -4.7% | 49.0% | 14.7% | 469.6%Unprecedented high revenue growth. 469.6%; 4-period range -36.8% to 64.2%. Revenue growth: 469.6%, unprecedented high; 4-period mean 11.2%, range -36.8%-64.2%. | Chart
|
| EBITDA | -$0.83m | -$4.8m | -$1.8m | -$4.5m | -$2.2m | -$5.2m | -$3.1m | -$5.7m | -$1.8m | Chart |
| EBITDA margin % | -32.4%Unprecedented high ebitda margin. -32.4%; 4-period range -97.7% to -47.9%. EBITDA margin: -32.4%, unprecedented high; 4-period mean -76.6%, range -97.7%--47.9%. | -63.8%Outside range high ebitda margin. -63.8%; 3-period range -89.1% to -65.2%. EBITDA margin: -63.8%, above normal range; 3-period mean -74.2%, range -89.1%--65.2%. | -47.9% | -89.1%Outside range low ebitda margin. -89.1%; 3-period range -68.3% to -63.8%. EBITDA margin: -89.1%, below normal range; 3-period mean -65.8%, range -68.3%--63.8%. | -97.7%Outside range low ebitda margin. -97.7%; 4-period range -85.4% to -32.4%. EBITDA margin: -97.7%, below normal range; 4-period mean -60.3%, range -85.4%--32.4%. | -65.3% | -85.4% | -68.3% | -75.6% | Chart
|
| PBT | -$0.9m | -$6m | -$2.4m | -$0.01m | -$7.3m | -$0.01m | -$5.8m | -$0.02m | -$2.8m | Chart |
| NPAT | $3.2m | -$6m | -$2.4m | -$0.01m | -$7.3m | -$0.01m | -$5.8m | -$0.02m | -$2.8m | Chart |
| Operating cash flow | -$1m | -$0.94m | -$1m | -$3.1m | -$1.9m | -$5.6m | -$4.6m | -$0.01m | -$4.6m | Chart |
| OCF / EBITDA % | 120.8% | 19.7%Outside range low ocf / ebitda cash conversion. 19.7%; 3-period range 69.4% to 207.6%. OCF / EBITDA cash conversion: 19.7%, below normal range; 3-period mean 128.3%, range 69.4%-207.6%. | 58.5%Outside range low ocf / ebitda cash conversion. 58.5%; 4-period range 86.4% to 253.4%. OCF / EBITDA cash conversion: 58.5%, below normal range; 4-period mean 152.9%, range 86.4%-253.4%. | 69.4% | 86.4% | 107.9% | 150.9% | 0.2%Outside range high ocf / ebitda cash conversion. 207.6%; 3-period range 19.7% to 108%. OCF / EBITDA cash conversion: 207.6%, above normal range; 3-period mean 65.7%, range 19.7%-108.0%. | 253.3%Unprecedented high ocf / ebitda cash conversion. 253.4%; 4-period range 58.5% to 150.9%. OCF / EBITDA cash conversion: 253.4%, unprecedented high; 4-period mean 104.1%, range 58.5%-150.9%. | Chart
|
| FCF pre-lease | -$1.1m | -$0.94m | -$1.1m | -$3.1m | -$1.9m | -$5.6m | -$4.7m | -$0.01m | -$4.8m | Chart |
| ROE % | 104.7% | 256.1% | -191.2% | -145.1% | -157.7% | -108.7% | -30.5% | -81.1% | -9.9% | Chart |
| Net debt | $0.02m | $14.5m | $14m | $12.5m | $13.7m | $11.5m | $10m | $6.9m | $10.9m | Chart |
| Net debt / EBITDA | -0.03x | -3.05x | -7.82x | -2.8x | -6.16x | -2.24x | -3.26x | -1.21x | -5.95x | Chart
|
| Debtor days | 114 | 67 | 91 | 103Outside range high debtor days. 103d; 3-period range 40d to 77d. Debtor days: 102.7 days, above normal range; 3-period mean 61.2 days, range 40.3 days-76.9 days. | 170Unprecedented high debtor days. 170d; 4-period range 86d to 145d. Debtor days: 170.4 days, unprecedented high; 4-period mean 108.9 days, range 86.2 days-144.6 days. | 77 | 86Outside range low debtor days. 86d; 4-period range 91d to 170d. Debtor days: 86.2 days, below normal range; 4-period mean 130.0 days, range 91.2 days-170.4 days. | 40Outside range low debtor days. 40d; 3-period range 67d to 103d. Debtor days: 40.3 days, below normal range; 3-period mean 82.1 days, range 66.6 days-102.7 days. | 145 | Chart
|
| Inventory days | 174Unprecedented low inventory days. 174d; 4-period range 655d to 1,658d. Inventory days: 173.7 days, unprecedented low; 4-period mean 1060.6 days, range 655.3 days-1658.2 days. | 548 | 655 | 1053 | 1138 | 684 | 791 | 741 | 1658 | Chart
|
| Total assets | $6.6m | $15.2m | $19m | $21.5m | $20.7m | $27m | $33.9m | $39.5m | $46.2m | Chart |
Reference: annolyse.ai/companies/mee
Note: Figures are shown as reported. Half-year and full-year absolute values are not directly comparable. Growth rates and ratios are the meaningful comparison across mixed periods.
These charts use verified published filing periods only. Gaps are not interpolated, and mixed half-year/full-year histories are split into separate series.
Reported revenue across covered periods.
Like-period revenue growth where comparable.
Company-specific earnings measure where disclosed.
EBITDA-equivalent margin where revenue and earnings are source-backed.
Statutory profit after tax.
Cash generated from operations.
Additional verified filing metrics for this company. Each point links back to a published briefing period in the source data contract.
Cash conversion against earnings.
Operating cash flow less capex before leases.
Return on equity.
Borrowings less cash; negative values indicate net cash.
Receivables days where the working-capital inputs are source-backed.
Inventory days where the working-capital inputs are source-backed.
Per-period working-capital absorption or release, from the same published history. Positive values are working-capital build; negative values are release.
The setup & the reality
The latest result is checked against what the prior briefing said to watch.
Historical setup
From Capital raise puts Me Today's debt headroom in focus
No quantitative targets were supplied. HY25 revenue of $3.7m represented 50.1% of the full year, implying an essentially flat second half on revenue but a heavier H2 EBITDA loss of about -$3.0m versus -$1.8m in H1. Operating cash flow swung from -$1.0m in H1 to roughly $0.1m positive in H2, again pointing to working-capital timing rather than improving underlying economics. Release commentary flags that a King Honey disposal will be reported in FY26, which will reshape the segment mix but is not reflected in current numbers.
Open questions
This briefing cannot assess going-concern conclusions, the commercial terms of the King Honey disposal, or the response of the major Chinese honey customer beyond what release commentary discloses.
Archive
Every published Annolyse briefing for this company appears here in reverse chronological order.
HY26 · Released 26 February 2026
A NZ$4.1m discontinued-operation gain funded a balance-sheet reset, but continuing operations stayed loss-making on a sharply lower revenue base.
FY25 · Released 28 August 2025
The NZ$2.6m capital raised is relevant to debt headroom, while borrowings and gearing remain the direct evidence.
HY25 · Released 28 February 2025
Revenue grew 64.2% and losses improved 66.5%, yet equity dropped 72.5% and cash conversion of 58.5% sits below the 152.9% historical mean.
FY24 · Released 29 August 2024
China manuka demand weakness pushed revenue below the historical baseline, leaving equity of NZ$3.6m against NZ$15.4m of gross borrowings.
HY24 · Released 28 February 2024
EBITDA loss narrowed 27.7% but a customer write-down deepened the NPAT loss to NZ$7.3m and forced a debt restructure plan.
FY23 · Released 29 August 2023
Losses narrowed materially, but a $5.6m operating cash burn left only $0.9m of cash against $12.4m of borrowings.
HY23 · Released 1 March 2023
Honey-led top-line growth produced negative operating leverage as the EBITDA loss widened and equity fell 32.4% to NZ$19.0m.
FY21 · Released 29 August 2022
Revenue rose 14.7% but a NZ$14.1m honey segment deterioration drove the PBT loss to NZ$22.1m even as a capital raise rebuilt cash.
HY22 · Released 29 November 2021
Revenue grew 469.6% on a new honey segment, but inventory days hit 1,658 and operating cash outflow widened to $4.6m.
Get the next Me Today result briefing and five-year history updates by email.